Ratings by BNP Paribas Exane (Navaan Ty)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 4/28/2026 | Organon & Co. | OGN | Downgrade | Neutral (Outperform) |
13.16 (13.76) |
4.56% | Details | |
| 11/21/2025 | Hologic | HOLX | Downgrade | Neutral (Outperform) |
74.12 (76.01) |
2.55% | Details | |
| 10/27/2025 | Natera | NTRA | Upgrade | Neutral (Underperform) |
192.51 (320.76) |
66.62% | Details | |
| 5/22/2025 | Organon & Co. | OGN | Maintain | Outperform (N/A) |
|
Details | ||
| 8/16/2023 | Revance Therapeutic | RVNC | Upgrade | Neutral (Underperform) |
18.80 (3.65) |
-80.59% | Details | |
| 5/30/2023 | Kenvue Inc | KVUE | New Coverage | Neutral (N/A) |
26.33 (18.75) |
-28.79% | Details | |
| 3/20/2023 | The Beauty Health Company | SKIN | Upgrade | Neutral (Underperform) |
11.31 (0.68) |
-93.99% | Details | |
| 12/8/2022 | Natera | NTRA | New Coverage | Underperform (N/A) |
38.46 (192.51) |
400.55% | Details | |
| 12/8/2022 | Hologic | HOLX | New Coverage | Outperform (N/A) |
73.80 (76.01) |
2.99% | Details | |
| 12/8/2022 | The Beauty Health Company | SKIN | New Coverage | Underperform (N/A) |
10.96 (0.68) |
-93.8% | Details | |
| 12/8/2022 | Evolus | EOLS | New Coverage | Outperform (N/A) |
7.06 (9.08) |
28.61% | Details | |
| 12/8/2022 | Abbvie | ABBV | New Coverage | Neutral (N/A) |
165.40 (259.99) |
57.19% | Details | |
| 12/8/2022 | Organon & Co. | OGN | New Coverage | Outperform (N/A) |
26.08 (13.16) |
-49.54% | Details | |
| 12/8/2022 | Revance Therapeutic | RVNC | New Coverage | Underperform (N/A) |
21.37 (3.65) |
-82.92% | Details |
